Clinical Pharmacology & Therapeutics - Issue - nature.com science feeds

In This Issue

2009-11-16

In This Issue

Clinical Pharmacology & Therapeutics 86, 571 (December 2009). doi:10.1038/clpt.2009.229

Neonatal Pharmacology: Rational Therapeutics for the Most Vulnerable

L James — 2009-11-16

Neonatal Pharmacology: Rational Therapeutics for the Most Vulnerable

Clinical Pharmacology & Therapeutics 86, 573 (December 2009). doi:10.1038/clpt.2009.212

Authors: L James & S Ito

Highlights

2009-11-16

Highlights

Clinical Pharmacology & Therapeutics 86, 578 (December 2009). doi:10.1038/clpt.2009.230

Author:

ASCPT News

2009-11-16

ASCPT News

Clinical Pharmacology & Therapeutics 86, 580 (December 2009). doi:10.1038/clpt.2009.220

Pediatric Drug Development: Concepts and Applications

S M MacLeod — 2009-11-16

Pediatric Drug Development: Concepts and Applications

Clinical Pharmacology & Therapeutics 86, 583 (December 2009). doi:10.1038/clpt.2009.192

Author: S M MacLeod

Clinical Trials in Neonates: A Therapeutic Imperative

R M Ward — 2009-11-16

Clinical Trials in Neonates: A Therapeutic Imperative

Clinical Pharmacology & Therapeutics 86, 585 (December 2009). doi:10.1038/clpt.2009.207

Authors: R M Ward & S E Kern

Can We Afford It?: Ethical Consideration of Expensive Drug Treatment for Neonates and Infants

R Zlotnik Shaul — 2009-11-16

Can We Afford It?: Ethical Consideration of Expensive Drug Treatment for Neonates and Infants

Clinical Pharmacology & Therapeutics 86, 587 (December 2009). doi:10.1038/clpt.2009.211

Authors: R Zlotnik Shaul & D Vitale

Clinical Trial Design in Neonatal Pharmacology: Effect of Center Differences, With Lessons From the Pediatric Oncology Cooperative Research Experience

C Moran — 2009-11-16

Clinical Trial Design in Neonatal Pharmacology: Effect of Center Differences, With Lessons From the Pediatric Oncology Cooperative Research Experience

Clinical Pharmacology & Therapeutics 86, 589 (December 2009). doi:10.1038/clpt.2009.175

Authors: C Moran, P B Smith, M Cohen-Wolkowiez & D K Benjamin

The Road From Discovery to Clinic: Adiponectin as a Biomarker of Metabolic Status

C M Kusminski — 2009-11-16

The Road From Discovery to Clinic: Adiponectin as a Biomarker of Metabolic Status

Clinical Pharmacology & Therapeutics 86, 592 (December 2009). doi:10.1038/clpt.2009.155

Authors: C M Kusminski & P E Scherer

Current Understanding of the Pharmacogenomics of Metformin

O Zolk — 2009-11-16

Current Understanding of the Pharmacogenomics of Metformin

Clinical Pharmacology & Therapeutics 86, 595 (December 2009). doi:10.1038/clpt.2009.144

Author: O Zolk

Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?

B Renner — 2009-11-16

Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?

Clinical Pharmacology & Therapeutics 86, 599 (December 2009). doi:10.1038/clpt.2009.65

Authors: B Renner & K Brune

No Obvious Extra Cardiovascular Risk Associated With Low-Dose NSAIDs

N Moore — 2009-11-16

No Obvious Extra Cardiovascular Risk Associated With Low-Dose NSAIDs

Clinical Pharmacology & Therapeutics 86, 600 (December 2009). doi:10.1038/clpt.2009.66

Author: N Moore

Do NSAIDs Actually Protect Against Myocardial Infarction and Death?

E J van Beers — 2009-11-16

Do NSAIDs Actually Protect Against Myocardial Infarction and Death?

Clinical Pharmacology & Therapeutics 86, 601 (December 2009). doi:10.1038/clpt.2009.164

Authors: E J van Beers, J R de Groot & J G P Tijssen

Response to “No Obvious Extra Cardiovascular Risk Associated With Low-Dose NSAIDs,” “Do NSAIDs Actually Protect Against Myocardial Infarction and Death?,” and “Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?”

E L Fosbøl — 2009-11-16

Response to “No Obvious Extra Cardiovascular Risk Associated With Low-Dose NSAIDs,” “Do NSAIDs Actually Protect Against Myocardial Infarction and Death?,” and “Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?”

Clinical Pharmacology & Therapeutics 86, 602 (December 2009). doi:10.1038/clpt.2009.204

Authors: E L Fosbøl, G H Gislason, L Køber & C Torp-Pedersen

Genetic Influences on the Pharmacokinetics of Orally and Intravenously Administered Digoxin as Exhibited by Monozygotic Twins

A L Birkenfeld — 2009-11-16

Genetic Influences on the Pharmacokinetics of Orally and Intravenously Administered Digoxin as Exhibited by Monozygotic Twins

Clinical Pharmacology & Therapeutics 86, 605 (December 2009). doi:10.1038/clpt.2009.170

Authors: A L Birkenfeld, J Jordan, U Hofmann, A Busjahn, G Franke, N Krüger, S Igel, T Mürdter, S Drescher, S Shi, S Engeli, M Schwab, M Eichelbaum, F C Luft & M F Fromm

Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients

W Zhao — 2009-11-16

Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients

Clinical Pharmacology & Therapeutics 86, 609 (December 2009). doi:10.1038/clpt.2009.210

Authors: W Zhao, V Elie, G Roussey, K Brochard, P Niaudet, V Leroy, C Loirat, P Cochat, S Cloarec, J L André, F Garaix, A Bensman, M Fakhoury & E Jacqz-Aigrain

Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple Sponsors

J A Wagner — 2009-11-16

Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple Sponsors

Clinical Pharmacology & Therapeutics 86, 619 (December 2009). doi:10.1038/clpt.2009.88

Authors: J A Wagner, E C Wright, M M Ennis, M Prince, J Kochan, D J R Nunez, B Schneider, M-D Wang, Y Chen, S Ghosh, B J Musser & M T Vassileva

Escitalopram Is a Weak Inhibitor of the CYP2D6-Catalyzed O-Demethylation of (+)-Tramadol but Does Not Reduce the Hypoalgesic Effect in Experimental Pain

L Noehr-Jensen — 2009-11-16

Escitalopram Is a Weak Inhibitor of the CYP2D6-Catalyzed O-Demethylation of (+)-Tramadol but Does Not Reduce the Hypoalgesic Effect in Experimental Pain

Clinical Pharmacology & Therapeutics 86, 626 (December 2009). doi:10.1038/clpt.2009.154

Authors: L Noehr-Jensen, S T Zwisler, F Larsen, S H Sindrup, P Damkier & K Brosen

Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study

S Willmann — 2009-11-16

Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study

Clinical Pharmacology & Therapeutics 86, 634 (December 2009). doi:10.1038/clpt.2009.151

Authors: S Willmann, A N Edginton, K Coboeken, G Ahr & J Lippert

Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects

R E Steinert — 2009-11-16

Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects

Clinical Pharmacology & Therapeutics 86, 644 (December 2009). doi:10.1038/clpt.2009.159

Authors: R E Steinert, B Poller, M C Castelli, K Friedman, A R Huber, J Drewe & C Beglinger

Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia

J C Panetta — 2009-11-16

Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia

Clinical Pharmacology & Therapeutics 86, 651 (December 2009). doi:10.1038/clpt.2009.162

Authors: J C Panetta, A Gajjar, N Hijiya, L J Hak, C Cheng, W Liu, C H Pui & M V Relling

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

R Krishna — 2009-11-16

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

Clinical Pharmacology & Therapeutics 86, 659 (December 2009). doi:10.1038/clpt.2009.167

Authors: R Krishna, B Gumbiner, C Stevens, B Musser, M Mallick, S Suryawanshi, L Maganti, H Zhu, T H Han, L Scherer, B Simpson, D Cosgrove, K Gottesdiener, J Amatruda, B J Rolls, J Blundell, G A Bray, K Fujioka, S B Heymsfield, J A Wagner & G A Herman

Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a Glucagon-Like Peptide-2 Analog in Neonates and Infants With Short-Bowel Syndrome

M S Mouksassi — 2009-11-16

Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a Glucagon-Like Peptide-2 Analog in Neonates and Infants With Short-Bowel Syndrome

Clinical Pharmacology & Therapeutics 86, 667 (December 2009). doi:10.1038/clpt.2009.199

Authors: M S Mouksassi, J F Marier, J Cyran & A A Vinks

Sustained Neurobehavioral Effects of Exposure to SSRI Antidepressants During Development: Molecular to Clinical Evidence

T F Oberlander — 2009-11-16

Sustained Neurobehavioral Effects of Exposure to SSRI Antidepressants During Development: Molecular to Clinical Evidence

Clinical Pharmacology & Therapeutics 86, 672 (December 2009). doi:10.1038/clpt.2009.201

Authors: T F Oberlander, J A Gingrich & M S Ansorge

Developmental Pharmacogenetics: A General Paradigm for Application to Neonatal Pharmacology and Toxicology

J S Leeder — 2009-11-16

Developmental Pharmacogenetics: A General Paradigm for Application to Neonatal Pharmacology and Toxicology

Clinical Pharmacology & Therapeutics 86, 678 (December 2009). doi:10.1038/clpt.2009.195

Author: J S Leeder

ERRATUM: The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies

2009-11-16

ERRATUM: The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies

Clinical Pharmacology & Therapeutics 86, 683 (December 2009). doi:10.1038/clpt.2009.174

CORRIGENDUM: Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease

2009-11-16

CORRIGENDUM: Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease

Clinical Pharmacology & Therapeutics 86, 683 (December 2009). doi:10.1038/clpt.2009.180